Cytoreductive SBRT Plus Nivo/Ipi for mRCC: CYTOSHRiNk Phase II Trial Reveals Promising Safety and Response Durability

Cytoreductive SBRT Plus Nivo/Ipi for mRCC: CYTOSHRiNk Phase II Trial Reveals Promising Safety and Response Durability

At a recent international academic symposium, Dr. Aly-Khan A. Lalani from McMaster University presented the primary results of the CYTOSHRINK study (Abstract 416). This randomized Phase II trial evaluated the efficacy and safety of cytoreductive stereotactic body radiotherapy (SBRT) combined with nivolumab plus ipilimumab (Nivo+Ipi) in patients with treatment-naïve metastatic clear cell renal cell carcinoma (mRCC).
Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines

Northern Breast Cancer Forum 2026 | Professor Peng Yuan: Driving Clinical Transformation Through “Three New Forces” and Anticipating Key Updates in the 2026 CSCO Breast Cancer Guidelines

As China’s flagship academic event in breast cancer at the start of each year, the Northern Breast Cancer Forum continues to bridge global scientific advances with localized clinical practice. From the SERENA-6 trial, which pioneers molecular monitoring for endocrine resistance, to the rapid rise of Trop-2–targeted ADCs and expanded access to PI3K/AKT/mTOR pathway inhibitors under national insurance coverage, the past year has witnessed profound shifts in breast cancer management.
CASH 2026 | Academician Tao Cheng: From “Hematologic Ecology” to a “Greater Hematology” Vision—Charting a New Blueprint for Hematology in China’s 15th Five-Year Plan

CASH 2026 | Academician Tao Cheng: From “Hematologic Ecology” to a “Greater Hematology” Vision—Charting a New Blueprint for Hematology in China’s 15th Five-Year Plan

From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin. Coinciding with the launch of China’s 15th Five-Year Plan, the conference centered on the theme “Tianjin: Renewing Momentum, Intelligence Leading the Future.” With a forward-looking perspective, the meeting focused on the systemic evolution and ecological integration of hematology, exploring high-quality discipline development pathways and innovative models within the broader “Healthy China” framework.